Document is current
Any future updates will be listed below
-
Authors
Pei, Guangsheng
Min, Jimin https://orcid.org/0000-0002-2309-7875
Rajapakshe, Kimal I.
Branchi, Vittorio https://orcid.org/0000-0002-6182-835X
Liu, Yunhe https://orcid.org/0000-0002-2120-952X
Selvanesan, Benson Chellakkan
Thege, Fredrik https://orcid.org/0000-0002-1822-4526
Sadeghian, Dorsay
Zhang, Daiwei
Cho, Kyung Serk
Chu, Yanshuo
Dai, Enyu
Han, Guangchun
Li, Mingyao https://orcid.org/0000-0001-8180-0621
Yee, Cassian https://orcid.org/0000-0002-4429-7307
Takahashi, Kazuki https://orcid.org/0009-0000-3348-3860
Garg, Bharti
Tiriac, Herve
Bernard, Vincent
Semaan, Alexander https://orcid.org/0000-0001-5424-3217
Grem, Jean L.
Caffrey, Thomas C.
Burks, Jared K. https://orcid.org/0000-0002-6173-9074
Lowy, Andrew M.
Aguirre, Andrew J. https://orcid.org/0000-0002-0701-6203
Grandgenett, Paul M.
Hollingsworth, Michael A. https://orcid.org/0000-0002-5255-8888
Guerrero, Paola A. https://orcid.org/0000-0002-7345-1246
Wang, Linghua https://orcid.org/0000-0001-9380-0266
Maitra, Anirban https://orcid.org/0000-0001-7923-9978
- License Information
-
More Information
Article History
Received: 6 February 2024
Accepted: 20 March 2025
First Online: 23 April 2025
Competing interests
: A.M. is listed as an inventor on a patent that has been licensed by Johns Hopkins University to Thrive Earlier Detection and serves as a consultant for Tezcat Biosciences. A.J.A. has consulted for Anji Pharmaceuticals, Affini-T Therapeutics, Arrakis Therapeutics, AstraZeneca, Boehringer Ingelheim, Kestrel Therapeutics, Merck, Mirati Therapeutics, Nimbus Therapeutics, Oncorus, Plexium, Quanta Therapeutics, Revolution Medicines, Reactive Biosciences, Riva Therapeutics, Servier Pharmaceuticals, Syros Pharmaceuticals, T-knife Therapeutics, Third Rock Ventures and Ventus Therapeutics; holds equity in Riva Therapeutics and Kestrel Therapeutics; and has research funding from Boehringer Ingelheim, Bristol Myers Squibb, Deerfield, Eli Lilly, Mirati Therapeutics, Novartis, Novo Ventures, Revolution Medicines and Syros Pharmaceuticals. The remaining authors declare no competing interests.
